Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) will post its Q3 2017 quarterly earnings results after the market closes on Thursday, November 2nd. Analysts expect Invivo Therapeutics Holdings Corp to post earnings of ($0.22) per share for the quarter.
Invivo Therapeutics Holdings Corp (NVIV) opened at 1.45 on Tuesday. The company’s market cap is $46.67 million. The company’s 50-day moving average is $1.42 and its 200 day moving average is $2.06. Invivo Therapeutics Holdings Corp has a 1-year low of $1.10 and a 1-year high of $5.90.
A number of equities analysts have issued reports on the company. Raymond James Financial, Inc. cut Invivo Therapeutics Holdings Corp from an “outperform” rating to a “market perform” rating in a report on Monday, July 31st. ValuEngine cut Invivo Therapeutics Holdings Corp from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.com-unik.info/2017/10/31/invivo-therapeutics-holdings-corp-nviv-scheduled-to-post-earnings-on-thursday.html.
About Invivo Therapeutics Holdings Corp
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
What are top analysts saying about Invivo Therapeutics Holdings Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Invivo Therapeutics Holdings Corp and related companies.